Previous studies have shown dabrafenib and trametinib plus osimertinib showed substantial efficacy among these EGFR TKIs resistant BRAF V600E mutant NSCLC patients, with PFS ranging from 2 to 13 months (41). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.